Abstract
A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.
Original language | English (US) |
---|---|
Pages (from-to) | 805-819 |
Number of pages | 15 |
Journal | CNS Drugs |
Volume | 19 |
Issue number | 10 |
DOIs | |
State | Published - Dec 1 2005 |
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Pharmacology (medical)